Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05973630Phase 1Active Not Recruiting

ATA-200 Gene Therapy Trial in Patients With LGMDR5

Role: lead

NCT05224505Phase 1Active Not Recruiting

ATA-100 (Formerly GNT0006) Gene Therapy Trial in Patients With LGMDR9

Role: lead

NCT06210672Withdrawn

Natural History Study in Patients With LGMDR5/2c

Role: lead

All 3 trials loaded